查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1402600

基因組癌症測試市場：依測試類型、癌症類型、技術、最終用戶、生物標記類型、服務供應商、地區

Genomic Cancer Testing Market, By Test Type, By Cancer Type, By Technology, By End-User, By Biomarker Type, By Service Provider, By Application, By Testing Setting, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球基因組癌症檢測市場規模預計將從 2023 年的 161.5 億美元增加到 2030 年的 476.2 億美元，預測期內複合年成長率為 16.7%。

報告範圍 報告詳情
基準年 2022年 2023年市場規模 161.5億美元
實際資料 2018-2021 預測期 2023-2030
預測期複合年成長率 16.70% 2030年市場規模預測 476.2億美元
圖 1. 2023 年依地區分類的基因組癌症檢測全球市場佔有率(%)
基因組癌症檢測市場-IMG1

基因組癌症檢測正在迅速改變腫瘤學領域。此測試分析癌細胞的基因組成，以深入了解導致患者疾病的突變。這種個體化方法使臨床醫生能夠根據個體的遺傳特徵量身定做治療方案，並選擇直接針對存在的異常的治療藥物。腫瘤基因組分析可以幫助預測對某些藥物的反應，檢查顯示高復發風險的遺傳標記，並確定可以阻斷以阻止癌症生長的生物途徑。隨著基因組技術的不斷進步，癌症檢測變得更加全面且負擔得起。預計這將在未來幾年顯著改善許多癌症患者的治療結果。

市場動態：

全球基因組癌症檢測市場主要是由全球癌症發生率上升以及由此產生的對精準醫學方法的需求所推動的。次世代定序（NGS）技術在生物標記識別中的日益成長的應用也推動了市場的成長。然而，特別是在開發中國家，缺乏基因組分析所需的基礎設施和熟練專家是一個主要問題。測試程序的高成本進一步限制了普及。然而，私人和公共機構為開發新型診斷工具提供的資金提供了利潤豐厚的機會。診斷公司和癌症中心之間的合作旨在擴大基因組分析的範圍。其他檢測可操作的基因組改變和檢驗診斷的策略措施將進一步刺激基因伴同性癌症檢測市場。此外，市場參與企業之間加強合作預計將在預測期內推動市場成長。例如，2023年4月，人工智慧和精準醫療領域的領導者Tempus宣布推出針對進行性或轉移性甲狀腺髓樣癌（MTC）或進行性或轉移性非髓樣癌（non-MTC）的新技術。 ）今天宣布了一項由禮來公司贊助的新合作夥伴關係，旨在擴大合格的癌症患者獲得基因組檢測的機會。此次合作將免費提供 Tempus 的分子分析，同時與醫生合作，透過廣泛的基因組測試幫助為患者提供資料驅動的治療。

本研究的主要特點

  • 本報告對全球基因組癌症檢測市場進行了詳細分析，並列出了以2022年為基準年的預測期（2023-2030）的市場規模和復合年成長率。
  • 本報告還揭示了各個區隔市場的潛在商機，並為該市場說明了一系列有吸引力的投資提案。
  • 本報告還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
  • 本報告根據公司亮點、產品系列、主要亮點、財務表現和策略等參數，介紹了全球基因組癌症檢測市場的主要企業。
  • 該報告的見解將使行銷人員和公司負責人能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
  • 全球基因組癌症檢測市場報告針對該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
  • 透過用於分析全球基因組癌症檢測市場的各種策略矩陣，將有助於相關人員做出決策。

目錄

第1章 研究目的與前提

  • 研究目標
  • 先決條件
  • 簡稱

第2章 市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map（COM）

第3章市場動態、法規及趨勢分析

  • 市場動態
    • 癌症發生率增加
    • 成本高
    • 癌症發生率增加
  • 影響分析
  • 主要亮點
  • 監管場景
  • 產品發布/核准
  • PEST分析
  • 波特的分析
  • 併購場景

第4章全球基因組癌症檢測市場 -冠狀病毒(COVID-19) 大流行的影響

  • 新型冠狀病毒感染疾病（COVID-19）的流行病學
  • 供需面分析
  • 經濟影響

第 5 章 2018-2030 年全球基因組癌症檢測市場（依檢測類型）

  • 基因組分析測試
  • 液體活體組織切片測試
  • 伴同性診斷測試
  • 藥物基因組測試
  • 遺傳性癌症檢測
  • 其他專門的基因組測試

第 6 章 全球基因組癌症檢測市場（以癌症類型），2018-2030 年

  • 乳癌
  • 肺癌
  • 大腸直腸癌
  • 攝護腺癌
  • 卵巢癌
  • 黑色素瘤
  • 白血病
  • 淋巴瘤
  • 某些其他癌症類型

第 7 章 2018-2030 年全球基因組癌症檢測市場（依技術）

  • 下一代定序（NGS）
  • 聚合酶鍊式反應 (PCR)
  • 螢光原位雜合反應（FISH）
  • 微陣列
  • 免疫組織化學 (IHC)
  • 其他基因組測試技術

第 8 章 全球基因組癌症檢測市場，依最終用戶分類，2018-2030 年

  • 醫院
  • 診斷實驗室
  • 學術研究所
  • 癌症中心
  • 其他醫療保健提供者

第 9 章 全球基因組癌症檢測市場（依生物標記類型），2018-2030 年

  • 基因生物標記
  • 蛋白質生物標記
  • 分子生物標記
  • 磊晶生物標記

第 10 章 全球基因組癌症檢測市場（依服務供應商分類），2018-2030 年

  • 診斷實驗室
  • 生技公司
  • 製藥公司
  • 受託研究機構（CRO）

第11章 全球基因組癌症檢測市場（依地區），2018-2030

  • 北美洲
  • 美國
  • 加拿大
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
  • 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太地區
  • 中東
  • GCC
  • 以色列
  • 其他中東地區
  • 非洲
  • 北非
  • 中部非洲
  • 南非

第12章競爭形勢

  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • Qiagen NV
  • F.Hoffmann-La Roche Ltd.
  • Foundation Medicine, Inc.（Roche）
  • Invitae Corporation
  • NeoGenomics Laboratories, Inc.
  • Myriad Genetics, Inc.
  • Genomic Health, Inc.（Exact Sciences Corporation）
  • Caris Life Sciences
  • ArcherDX, Inc.（Invitae Corporation）
  • Guardant Health, Inc.
  • Personal Genome Diagnostics Inc.
  • Biocept, Inc.
  • Tempus Labs, Inc.

第13章

  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI5914

The global genomic cancer testing market size is expected to reach US$ 47.62 billion by 2030, from US$ 16.15 billion in 2023, at a CAGR of 16.7% during the forecast period.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 16.15 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 16.70% 2030 Value Projection: US$ 47.62 Bn
Figure 1. Global Genomic Cancer Testing Market Share (%), by Region, 2023
Genomic Cancer Testing Market - IMG1

Genomic cancer testing is rapidly transforming the field of oncology. It involves analyzing the genetic makeup of cancer cells to gain insights into the mutations driving a patient's disease. This personalized approach enables clinicians to tailor treatment based on an individual's genetic profile and select therapeutics that directly target the abnormalities present. The genomic analysis of a tumor helps predict response to certain drugs, checks for genetic markers that may indicate higher risk of recurrence, and pinpoints biological pathways that can be blocked to stop cancer growth. With continued advances in genomic technologies, cancer testing is becoming more comprehensive and affordable. This is expected to significantly improve outcomes for many cancer patients in the coming years.

Market Dynamics:

The global genomic cancer testing market is primarily driven by rising cancer burden worldwide and subsequent demand for precision medicine approaches. Growing application of next-generation sequencing (NGS) technologies for biomarker identification is also fueling market growth. However, lack of infrastructure and skilled professionals required for genomic analysis poses a major challenge, especially in developing nations. High cost of testing procedures further limits widespread adoption. Yet funding from private and public bodies to develop novel diagnostic tools presents lucrative opportunities. Partnerships between diagnostic companies and cancer centers aim to expand access to genomic profiling. Other strategic initiatives to detect actionable genomic alterations and validate companion diagnostics will further stimulate the genomic cancer testing market. MOrevoer, increasing collaboration between market players is expected to drive the market growth over forecast period. For instance, in April 2023, Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration sponsored by Eli Lilly and Company designed to expand access to genomic testing for eligible patients who have advanced or metastatic medullary thyroid cancer (MTC) OR advanced or metastatic non-medullary thyroid cancer (non-MTC). This collaboration offers Tempus' molecular profiling offerings at no cost while simultaneously working with physicians to support them in providing data-driven treatment to their patients with the use of broad-panel genomic testing.

Key features of the study:

  • This report provides in-depth analysis of the global genomic cancer testing market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global genomic cancer testing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Illumina, Inc., Thermo Fisher Scientific, Inc., Qiagen N.V., F. Hoffmann-La Roche Ltd., Foundation Medicine, Inc. (Roche), Invitae Corporation, NeoGenomics Laboratories, Inc., Myriad Genetics, Inc., Genomic Health, Inc. (Exact Sciences Corporation), Caris Life Sciences, ArcherDX, Inc. (Invitae Corporation), Guardant Health, Inc., Personal Genome Diagnostics Inc., Biocept, Inc., and Tempus Labs, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global genomic cancer testing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global genomic cancer testing market

Detailed Segmentation:

  • Global Genomic Cancer Testing Market, By Test Type:
    • Genomic Profiling Tests
    • Liquid Biopsy Tests
    • Companion Diagnostic Tests
    • Pharmacogenomic Tests
    • Hereditary Cancer Tests
    • Other specialized genomic tests
  • Global Genomic Cancer Testing Market, By Cancer Type:
    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Ovarian Cancer
    • Melanoma
    • Leukemia
    • Lymphoma
    • Other specific cancer types
  • Global Genomic Cancer Testing Market, By Technology:
    • Next-Generation Sequencing (NGS)
    • Polymerase Chain Reaction (PCR)
    • Fluorescence In Situ Hybridization (FISH)
    • Microarray
    • Immunohistochemistry (IHC)
    • Other genomic testing technologies
  • Global Genomic Cancer Testing Market, By End User:
    • Hospitals
    • Diagnostic Laboratories
    • Academic and Research Institutions
    • Cancer Centers
    • Other healthcare providers
  • Global Genomic Cancer Testing Market, By Biomarker Type:
    • Genetic Biomarkers
    • Protein Biomarkers
    • Molecular Biomarkers
    • Epigenetic Biomarkers
  • Global Genomic Cancer Testing Market, By Service Provider:
    • Diagnostic Laboratories
    • Biotechnology Companies
    • Pharmaceutical Companies
    • Contract Research Organizations (CROs)
  • Global Genomic Cancer Testing Market, By Application:
    • Targeted Therapy Selection
    • Disease Monitoring
    • Prognostic Testing
    • Companion Diagnostics
    • Risk Assessment
    • Pharmacogenomic Testing
  • Global Genomic Cancer Testing Market, By Testing Setting:
    • In-House Testing
    • Outsourced Testing
  • Global Genomic Cancer Testing Market, By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa
  • Company Profiles:
    • Illumina, Inc.
    • Thermo Fisher Scientific, Inc.
    • Qiagen N.V.
    • F. Hoffmann-La Roche Ltd.
    • Foundation Medicine, Inc. (Roche)
    • Invitae Corporation
    • NeoGenomics Laboratories, Inc.
    • Myriad Genetics, Inc.
    • Genomic Health, Inc. (Exact Sciences Corporation)
    • Caris Life Sciences
    • ArcherDX, Inc. (Invitae Corporation)
    • Guardant Health, Inc.
    • Personal Genome Diagnostics Inc.
    • Biocept, Inc.
    • Tempus Labs, Inc.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Genomic Cancer Testing, By Test Type
    • Market Genomic Cancer Testing, By Cancer Type
    • Market Genomic Cancer Testing, By Technology
    • Market Genomic Cancer Testing, By End User
    • Market Genomic Cancer Testing, By Biomarker Type
    • Market Genomic Cancer Testing, By Service Provider
    • Market Genomic Cancer Testing, By Application
    • Market Genomic Cancer Testing, By Testing Setting
    • Market Genomic Cancer Testing, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Increasing Cancer Incidence
    • High Costs
    • Increasing Cancer Incidence
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Genomic Cancer Testing Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Genomic Cancer Testing Market , By Test Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Genomic Profiling Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Liquid Biopsy Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Companion Diagnostic Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Pharmacogenomic Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Hereditary Cancer Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Other specialized genomic tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

6. Global Genomic Cancer Testing Market , By Cancer Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Breast Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Lung Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Colorectal Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Prostate Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Ovarian Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Melanoma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Leukemia
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Lymphoma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Other specific cancer types
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

7. Global Genomic Cancer Testing Market , By Technology, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Next-Generation Sequencing (NGS)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Polymerase Chain Reaction (PCR)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Fluorescence In Situ Hybridization (FISH)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Microarray
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Immunohistochemistry (IHC)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Other genomic testing technologies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

8. Global Genomic Cancer Testing Market , By End User, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Diagnostic Laboratories
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Academic and Research Institutions
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Cancer Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Other healthcare providers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

9. Global Genomic Cancer Testing Market , By Biomarker Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Genetic Biomarkers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Protein Biomarkers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Molecular Biomarkers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Epigenetic Biomarkers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

10. Global Genomic Cancer Testing Market , By Service Provider, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019- 2030
    • Segment Trends
  • Diagnostic Laboratories
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Biotechnology Companies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Pharmaceutical Companies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Contract Research Organizations (CROs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

11. Global Genomic Cancer Testing Market , By Region, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Region, 2019-2030
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Service Provider, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Testing Setting, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • North Africa
  • Central Africa
  • South Africa

12. Competitive Landscape

  • Illumina, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Thermo Fisher Scientific, Inc.
  • Qiagen N.V.
  • F.Hoffmann-La Roche Ltd.
  • Foundation Medicine, Inc. (Roche)
  • Invitae Corporation
  • NeoGenomics Laboratories, Inc.
  • Myriad Genetics, Inc.
  • Genomic Health, Inc. (Exact Sciences Corporation)
  • Caris Life Sciences
  • ArcherDX, Inc. (Invitae Corporation)
  • Guardant Health, Inc.
  • Personal Genome Diagnostics Inc.
  • Biocept, Inc.
  • Tempus Labs, Inc.
  • Analyst Views

13. Section

  • Research Methodology
  • About us